This inventor holds 4 USPTO granted patents. Top assignee: Novo Nordisk A/s. Active years: 1998-2002.
Company Filing History:
Years Active: 1998-2002
Title: The Innovations of Karsten Lundgren
Introduction
Karsten Lundgren is a notable inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of diabetes and related conditions. With a total of 4 patents to his name, Lundgren's work has the potential to impact many lives.
Latest Patents
One of his latest patents is titled "Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines." This invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines for inhibiting liver glycogen phosphorylase. Another significant patent involves "Heterocyclic compounds," which presents novel piperidine compounds useful in the treatment and prevention of diabetes, particularly non-insulin dependent diabetes (NIDDM or type 2 diabetes). This patent addresses various treatment aspects, including overnight or meal treatment and the prevention of long-term complications such as retinopathy, neuropathy, nephropathy, and more.
Career Highlights
Karsten Lundgren is currently employed at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His work at Novo Nordisk has allowed him to focus on innovative solutions for diabetes management and treatment.
Collaborations
Throughout his career, Lundgren has collaborated with several talented individuals, including Palle Jakobsen and Marit Kristiansen. These collaborations have contributed to the advancement of his research and the development of impactful inventions.
Conclusion
Karsten Lundgren's contributions to the field of diabetes treatment through his innovative patents highlight his dedication to improving healthcare. His work continues to pave the way for advancements in pharmaceutical solutions.